CCL22
- Known as:
- CCL22
- Catalog number:
- 000029A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- CCL22
Related genes to: CCL22
- Gene:
- CCL22 NIH gene
- Name:
- C-C motif chemokine ligand 22
- Previous symbol:
- SCYA22
- Synonyms:
- MDC, STCP-1, ABCD-1, DC/B-CK, A-152E5.1, MGC34554
- Chromosome:
- 16q21
- Locus Type:
- gene with protein product
- Date approved:
- 1997-08-22
- Date modifiied:
- 2016-10-05
Related products to: CCL22
Related articles to: CCL22
- A deeper understanding of the immune-based pathogenesis of alopecia areata is essential for the development of novel targeted therapies. Compared to cytokines, chemokines exhibit substantially higher serum concentrations, offering a more robust approach for large-scale immune profiling. However, the complexity of chemokine interactions presents challenges in defining their precise roles in AA. To explore these dynamics, we conducted a scoping review and meta-analysis of 46 original research articles examining chemokine expression in skin and blood samples from AA patients; meta-analysis was performed when three or more studies assessed the same chemokine in comparable groups. Th1-associated chemokines-including CXCL9, CXCL10, CCL5, and CXCL11-were consistently elevated in AA, reflecting the known IFN-γ-driven response. A distinct Th2 chemokine signature was also observed, with increased levels of CCL13, CCL17, CCL22, and CX3CL1. Additionally, elevated levels of CCL2, CCL3, CCL4 (monocyte/dendritic cell recruitment), and CCL11, CCL24, and CCL26 (eosinophil recruitment) suggest the involvement of immune pathways beyond classical T helper subsets. Meta-analysis confirmed significantly elevated serum levels of CXCL9 (p = 0.003), CXCL10 (p = 0.004), CXCL8 (p < 0.001), and CCL17 (p < 0.001). These findings reveal a complex chemokine profile in AA, dominated by Th1 activity but also implicating Th2 and other immune pathways, highlighting the potential benefit of broader immunomodulatory strategies to address the multifaceted immune dysregulation underlying the disease. - Source: PubMed
Publication date: 2025/09/03
Van Caelenberg EliseBelpaire Arnovan Geel NanjaSpeeckaert Reinhart - Prenatal exposures to flame retardants (FRs), including legacy polybrominated diphenyl ethers (PBDEs) and alternative organophosphate FRs (OPFRs), are associated with adverse pregnancy outcomes. In animal and cell models, inflammation has been proposed as a potential pathway of FR-toxicity; however, data in humans is limited. In this study, we assessed whether levels of FRs are associated with diverse inflammatory biomarkers, reflecting potential mediating pathways. We leveraged mid-gestation maternal and fetal biospecimens, a timepoint that is often difficult to study due to ethical challenges. - Source: PubMed
Publication date: 2025/09/16
Nguyen VinceSehgal NehaLi LinGoin Dana EMorello-Frosch RachelWoodruff Tracey JVarshavsky JuliaPark June-SooGaw Stephanie LRobinson Joshua FEick Stephanie M - Skeletal muscle injuries are a common consequence of physical activity, repetitive movements, and trauma. Regulatory T cells (Treg) have recently been identified as critical mediators of immune repair response after injury, and treatments effectively targeting Treg may accelerate injury resolution. CCL22 is a chemokine that recruits CCR4-expressing cells, particularly Treg, to sites of inflammation or immune regulation, such as tumor microenvironments. When a sustained release formulation of polymeric microparticles (MP) delivering CCL22 (CCL22MP), was administered after cardiotoxin (CTx)-mediated muscle injury, significantly improved limb function was observed on days 3 and 5 post injury. Histologic evaluation of the injured limbs showed reduced area of injury in CCL22MP treated limbs. Analysis of the local immune populations revealed augmented Treg concentrations, as well as increased myeloid derived suppressor cell and neutrophil frequency. These findings reveal that amplifying local Treg to damaged areas improves outcomes, thus offering a translationally promising approach after muscle injury. - Source: PubMed
Publication date: 2025/08/22
Borrelli Matthew AWarunek Jordan JpLittle Steven RTurnquist Heth R - Numerous pre-vaccination factors are known to be associated with differential responses to influenza vaccination, including age, prior infection, vaccination history, immune cell frequencies, and transcriptomic profiles. However, plasma chemokines and cytokines are relatively unexplored. Given that older individuals have generally higher levels of inflammatory molecules in circulation, termed inflammaging, and also respond poorly to vaccination, plasma immune profiles likely play a role in effective response to influenza vaccination. - Source: PubMed
Publication date: 2025/08/13
Pickering HarryCarlock Michael ACappelletti MonicaGjertson David WRoss Ted MReed Elaine F - Controlled release systems, such as polymeric microparticles (MPs), have emerged as a promising solution to extend the bioavailability and reduce dosing frequency for biologic drugs; however, the formulation of these systems to encapsulate highly sensitive, hydrophilic biologic drugs within hydrophobic polymers remains a nontrivial task. Although scalable manufacturing and FDA approval of single emulsion processes encapsulating small molecules has been achieved, scaling more complex double emulsion processes to encapsulate hydrophilic biologics remains more challenging. : Here, we demonstrate that two hydrophilic, low-molecular-weight, recombinant chemokines, CCL22 and CCL2, can be encapsulated in poly(lactic-co-glycolic acid) (PLGA) MPs using a single emulsion method where the proteins are dissolved in an organic solvent during formulation. : As expected, we observed some differences in release kinetics from single emulsion MPs compared to double emulsion MPs, which traditionally have been used to encapsulate proteins. Single emulsion MPs exhibited a substantially reduced initial burst. Importantly, protein released from single emulsion CCL22-MPs also retained biological activity, as determined by a cell-based functional assay. Decreasing particle size or changing the polymer end group from PLGA-COOH to PLGA-OH increased the initial burst from single emulsion MPs, demonstrating tunability of release kinetics for protein-loaded, single emulsion MPs. Finally, to improve scalability and enable more precise control over MP formulations, the single emulsion process was adapted to a microfluidic, continuous manufacturing system, and the resulting MPs were evaluated similarly. : Altogether, this study demonstrates the feasibility of using a single emulsion encapsulation method for at least some protein biologics. - Source: PubMed
Publication date: 2025/08/14
Kobyra Julie APezzillo MichaelBentley Elizabeth RBalmert Stephen CSfeir CharlesLittle Steven R